Since we observed that the antigen-presenting ability of both monocytes and DCs was significantly reduced in elderly patients with sepsis, GM-CSF could be a therapeutic alternative to improve innate immune dysfunction, which shows promising utility for attenuating immunoparalysis in sepsis [32]. This evidence concerns the gene CSF2 and Sepsis.